Scancell
Scancell's mission is to develop products that stimulate the immune system to treat or prevent cancer.

Profile
Scancell’s mission is to develop products that stimulate the immune system to treat or prevent cancer.
In December 2006, Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.
Scancell’s first clinical candidate drug, ImmunoBody® is a DNA vaccine which is being developed for the treatment of melanoma.
Scancell began trading on AIM in 2008.
News and press releases
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·
BlueSkeye AI wins ‘One to Watch’ Award at Medilink Business Awards 2022
- 2nd February 2022 12:22 pm·
Data privacy startup ID Ward raises €1.1 million to launch its decentralised advertising technology
- 2nd February 2022 11:53 am·
NuVision Biotherapies announces the appointment of its new Chief Executive Officer and Chief Operating Officer
- 13th January 2022 11:43 am·
BlueSkeye AI shortlisted as a finalist for the Medilink Midlands Business Awards 2022
- 17th December 2021 12:40 pm·
University spin-out named best medtech start-up
- 29th November 2021 2:47 pm·
Green jobs at Cheesecake Energy
- 1st November 2021 4:07 pm·
Steve Cliffe joins BlueSkeye AI as it scales the development of its technology and customer portfolio
- 26th October 2021 9:36 am·
Cheesecake Energy announces new board appointments
- 5th October 2021 4:05 pm·
@scancellpharma on Twitter
$SCLP Encouraging early efficacy data from monotherapy part of ModiFY Phase 1/2 clinical trial https://tinyurl.com/vbjx9ejj $SCNLF $SCP #SCLP #SCNLF #SCP
$SCLP Scancell Holdings hails early 'very encouraging' results from phase I/II cancer trial https://tinyurl.com/2h87t6eh @scancellpharma $SCNLF #SCLP #SCNLF
Pleased to share the latest Outlook report from Trinity Delta focussing on Scancell’s antibody and vaccine oncology platforms.
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/sclp-outlook-230215.pdf
We are pleased to have been awarded an Indian patent for our Moditope® programme based on exploiting stress-induced post-translational modifications (siPTMs) such as citrullination to develop novel anti-cancer vaccines.
Scancell Holdings plc - Scancell announces positive response in COVIDITY trial
https://scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-announces-positive-response-in-covidity-trial_final_13.02.23.pdf
We are thrilled to welcome Dr Jean-Michel Cosséry to Scancell as Non-Executive Chairman of the Board.
https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/scancell-appoints-dr-jean-michel-coss%C3%A9ry-as-non-executive-chairman-of-the-board-01.02.23-final.pdf
$SCLP Scancell announces appointment of Dr Jean-Michel Cosséry as its non-executive chairman with immediate effect https://tinyurl.com/29g3omwc @scancellpharma $SCNLF #SCLP #SCNLF
We are pleased to have been awarded a Singaporean patent on our anti-glycan monoclonal antibody with specificity for the sialyl-di-Lewisᵃ glycan expressed on glycoproteins